Business Context and Reporting Period
This Form 8-K is a current report filed by resTORbio, Inc. (not Adicet Bio, Inc.) on September 18, 2018. The filing reports the appointment of a new executive officer and the terms of her employment agreement.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation terms:
- Base Salary: $345,000 annually.
- Performance Bonus: Targeted at up to 40% of the annual base salary.
- Equity Grant: Stock option to purchase 175,000 shares of common stock.
Material Changes
The primary material change is the appointment of Meredith S. Manning as Chief Commercial Officer, effective September 17, 2018. Ms. Manning joins from Shire plc, where she served as Vice President, Global Product Strategy Lead Hemophilia. She previously held roles at Vertex Pharmaceuticals and Pfizer.
Outlook, Risks, and Unusual Items
The filing details severance provisions under the Employment Agreement:
- Termination without cause/Good reason: Eligible for 0.5x base salary and up to 6 months of COBRA contributions.
- Change in Control followed by termination: Eligible for 1.0x (base salary + average target incentive), 100% acceleration of time-based equity awards, and up to 18 months of COBRA contributions.
No specific risks, contingencies, or unusual financial items are disclosed in this report.
Investor Verification Checklist
- Verify the registrant name is resTORbio, Inc. (the input metadata incorrectly listed Adicet Bio, Inc.).
- Confirm the effective date of the Chief Commercial Officer appointment (September 17, 2018).
- Review the attached Employment Agreement (Exhibit 99.1) for full definitions of "cause," "good reason," and "change in control."
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.